School of Medicine
Showing 1-20 of 41 Results
-
Anusha Kalbasi, M.D.
Associate Professor of Radiation Oncology (Radiation Therapy)
BioDr. Kalbasi is a board-certified radiation oncologist and physician-scientist at the Stanford Cancer Institute. He is also an associate professor of radiation oncology at Stanford Medicine and a project member of the Parker Institute for Cancer Immunotherapy.
In the clinic, Dr. Kalbasi specializes in the diagnosis and treatment of solid tumors, especially sarcoma and melanoma, with a focus on bringing new treatments to patients. This focus includes using advanced techniques in radiation oncology and cancer immunotherapy.
Dr. Kalbasi's NIH-funded laboratory studies the cancer-immune interface in various therapeutic contexts, including T cell therapy, cytokine therapy and innate immune agonism. The lab has described tumor cell-, T cell- and myeloid cell-intrinsic mechanisms of resistance to therapy and approaches to overcome therapy resistance. Dr. Kalbasi is also an experienced leader of clinical trials related to immunotherapy, T cell therapy and radiation therapy.
Prior to his arrival at Stanford Health Care, Dr. Kalbasi was assistant professor of radiation oncology in the David Geffen School of Medicine at UCLA and chief of sarcoma radiotherapy at the UCLA Jonsson Comprehensive Cancer Center. During his tenure, he was named a NextGen Star by the American Association of Cancer Research in recognition for excellence in cancer research.
Dr. Kalbasi’s work has been published in leading journals including Nature, Science Translational Medicine, JAMA Oncology, Lancet Oncology, Nature Cancer and Cancer Discovery. He has served as a peer reviewer for multiple prestigious journals, including the Proceedings of the National Academy of Sciences, Cell and the Journal of Clinical Investigation. He has also presented research to his peers at the American Association for Cancer Research and the American Institute of Chemical Engineers. -
Aya Kamaya, MD
Professor of Radiology (Body Imaging)
Current Research and Scholarly InterestsHepatobiliary imaging
Hepatocellular carcinoma
Urologic imaging
Gynecologic imaging
Thyroid imaging
Novel ultrasound technologies
Perfusion CT imaging of abdominal tumors -
Michael J. Kaplan, MD
Professor of Otolaryngology - Head & Neck Surgery at the Stanford University Medical Center, Emeritus
Current Research and Scholarly Interests1) New therapeutic approaches for head and neck cancer, including immune stimulation possibilities (IRX-2 protocol), integration of biological modifiers, and, eventually, genetic approaches.
2) Head and neck cancer stem cells: identification, characterization, control--in conjunction with the Irv Weissman and Michael Clarke labs in the Stem Cell Institute
3) Development of innovative surgical methods at the anterior cranial base -
Daniel Kapp
Professor of Radiation Oncology, Emeritus
Current Research and Scholarly InterestsGynecologic malignancies; Rectal/and cancer; Breast Cancer; Hodgkin's disease; Hyperthermia; intraoperative radiation therapy; High dose rate radiation therapy; Predictive assays; Patterns of tumor spread; Health care finance.
-
Amer Karam
Clinical Professor, Obstetrics & Gynecology - Gynecologic Oncology
BioDr. Amer Karam is a board-certified, fellowship-trained gynecologic surgeon and clinical professor in the Stanford Medicine Department of Obstetrics & Gynecology, Division of Gynecology Oncology. He specializes in gynecologic oncology, hospice and palliative care, hereditary gynecologic cancers, laparoscopic and robotic gynecologic surgery, and obstetrics and gynecology.
Dr. Karam attended medical school at the American University in Beirut. He completed his internship and residency at the Johns Hopkins Hospital in Baltimore, Maryland, before completing a fellowship in gynecologic oncology at the University of California Los Angeles and a fellowship in breast surgery at the Memorial Sloan-Kettering Cancer Center. Dr. Karam has a vested interest in minimally invasive and robotic surgery with a practice centered on this approach for the treatment of patients with gynecologic malignancy and complicated pelvic surgery. He is currently director of Robotic Surgery and Outreach in the Division of Gynecologic Oncology. -
Maya M. Kasowski
Assistant Professor of Medicine (Sean N Parker Center for Allergy and Asthma Research) of Pathology and, by courtesy, of Genetics
BioI am a clinical pathologist and assistant professor in the Departments of Medicine, Pathology, and Genetics (by courtesy) at Stanford. I completed my MD-PhD training at Yale University and my residency training and a post-doctoral fellowship in the Department of Genetics at Stanford University. My experiences as a clinical pathologist and genome scientist have made me passionate about applying cutting-edge technologies to primary patient specimens in order to characterize disease pathologies at the molecular level. The core focus of my lab is to study the mechanisms by which genetic variants influence the risk of disease through effects on intermediate molecular phenotypes.
-
Laurence Katznelson, MD
Professor of Neurosurgery and of Medicine (Endocrinology)
Current Research and Scholarly InterestsDr. Katznelson is an internationally known neuroendocrinologist and clinical researcher, with research expertise in the diagnosis and management of hypopituitarism, the effects of hormones on neurocognitive function, and the development of therapeutics for acromegaly and Cushings syndrome, and neuroendocrine tumors. Dr. Katznelson is the medical director of the multidisciplinary Stanford Pituitary Center, a program geared for patient management, clinical research and patient education
-
Mark A. Kay, M.D., Ph.D.
Dennis Farrey Family Professor of Pediatrics, and Professor of Genetics
Current Research and Scholarly InterestsMark A. Kay, M.D., Ph.D. Director of the Program in Human Gene Therapy and Professor in the Departments of Pediatrics and Genetics. Respected worldwide for his work in gene therapy for hemophilia, Dr. Kay and his laboratory focus on establishing the scientific principles and developing the technologies needed for achieving persistent and therapeutic levels of gene expression in vivo. The major disease models are hemophilia, hepatitis C, and hepatitis B viral infections.
-
Electron Kebebew, MD, FACS
Harry A. Oberhelman, Jr. and Mark L. Welton Professor
Current Research and Scholarly InterestsDr. Kebebew’s translational and clinical investigations have three main scientific goals: 1) to develop effective therapies for fatal, rare and neglected endocrine cancers, 2) to identify new methods, strategies and technologies for improving the diagnosis and treatment of endocrine neoplasms and the prognostication of endocrine cancers, and 3) to develop methods for precision treatment of endocrine tumors.
-
Ali Raza Khaki, MD
Clinical Assistant Professor, Medicine - Oncology
BioDr. Khaki is a medical oncologist and clinical assistant professor at Stanford University School of Medicine.
In his clinical practice, he treats patients with all forms of genitourinary cancer, including kidney, bladder, prostate, and testicular. He also regularly attends on the inpatient oncology service at Stanford Hospital.
With each patient, he is devoted to providing exceptional, humanistic care and has been recognized throughout his career for his humanism. As a medical student, he was named to the national Gold Humanism Honor Society and he received the Reza Gandjei Humanism Award as a medical resident at UCSF.
His research interests include novel therapies for genitourinary cancers, with a focus on urothelial cancer outcomes. He also has studied health care utilization and costs for end-of-life care of cancer patients.
Dr. Khaki has earned honors and recognition from the American Association for Cancer Research, American Society of Clinical Oncology, Bladder Cancer Advocacy Network, Conquer Cancer Foundation, and other organizations.
He has authored numerous articles on topics such as immunotherapy for urothelial cancer, management of cancer patients with COVID-19, and utilization of end-of-life care by cancer patients. In addition, he is an editor for HemOnc.org and theMednet, a physician-only online community where members share clinical questions and answers. -
Aziz Khan
Research Scientist, Stanford Cancer Institute Core
BioAziz Khan is a staff scientist at the Stanford Cancer Institute, where he develops reproducible pipelines and machine learning methods for integrative analysis of multi-omics data at bulk and single-cell resolution to understand tumor evolution and chromatin regulatory dynamics of tumor growth.
Aziz completed his PhD in Bioinformatics at Tsinghua University, China in 2016 followed by a three year postdoctoral training at the University of Oslo, Norway. During PhD and Postdoc his primary research emphasis was on regulatory genomics and epigenomics. He developed computational methods, tools, and resources to understand the (epi)genomic control of gene regulation in development and disease.
Apart from research, he is advocating for open science, open-source, preprints, and reproducibility in research. He is a contributor for Bioconda and also developed several open-source tools and resources such as JASPAR. He is ASAPbio and eLife Community Ambassador and co-founded ECRcentral (ecrcentral.org), a community initiative for early-career researchers. -
Saad A. Khan, MD
Assistant Professor of Medicine (Oncology)
BioDr. Khan is a fellowship-trained cancer specialist with board certification in oncology and hematology. He is an assistant professor in the Department of Medicine, Division of Oncology.
Dr. Khan focuses on the treatment of head and neck cancers, advanced thyroid cancers, and neuroendocrine tumors. He recognizes the broad effects of these conditions on daily living and aims to develop personalized, comprehensive treatment plans that optimize health and quality of life.
Dr. Khan’s research interests include therapeutic clinical trials as well as ways to reduce toxicities that some patients may experience when receiving cancer treatment. His research activities include ongoing clinical trials of targeted and immune therapy for aggressive thyroid cancer.
He has published numerous articles on his research discoveries in peer-reviewed journals such as the JAMA Oncology, Investigational New Drugs, and others. Topics include new drug treatments for small cell lung cancer and for cancers of the head and neck, racial and gender disparities in certain types of cancer, and management of the potentially toxic effects of cancer therapies.
Dr. Khan is a member of the NRG Head and Neck Committee. NRG brings together internationally recognized groups (the first words in their names form the acronym “NRG”) to conduct cancer clinical research and share study results. The objective is to inform clinical decision making and healthcare policy worldwide.
Dr. Khan is a member of the ECOG Head and Neck Core and Thoracic Committees. ECOG (Eastern Cooperative Oncology Group) is part of one of the five groups of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) Program.
He also is a member of the National Cancer Institute’s Central IRB for Early Phase Clinical Trials.
When not providing patient care or conducting research, Dr. Khan enjoys spending time with his family, hiking, and relaxing at the beach. -
Paul A. Khavari, MD, PhD
Carl J. Herzog Professor of Dermatology in the School of Medicine
Current Research and Scholarly InterestsWe work in epithelial tissue as a model system to study stem cell biology, cancer and new molecular therapeutics. Epithelia cover external and internal body surfaces and undergo constant self-renewal while responding to diverse environmental stimuli. Epithelial homeostasis precisely balances stem cell-sustained proliferation and differentiation-associated cell death, a balance which is lost in many human diseases, including cancer, 90% of which arise in epithelial tissues.
-
Chaitan Khosla
Wells H. Rauser and Harold M. Petiprin Professor and Professor of Chemistry and, by courtesy, of Biochemistry
Current Research and Scholarly InterestsResearch in this laboratory focuses on problems where deep insights into enzymology and metabolism can be harnessed to improve human health.
For the past two decades, we have studied and engineered enzymatic assembly lines called polyketide synthases that catalyze the biosynthesis of structurally complex and medicinally fascinating antibiotics in bacteria. An example of such an assembly line is found in the erythromycin biosynthetic pathway. Our current focus is on understanding the structure and mechanism of this polyketide synthase. At the same time, we are developing methods to decode the vast and growing number of orphan polyketide assembly lines in the sequence databases.
For more than a decade, we have also investigated the pathogenesis of celiac disease, an autoimmune disorder of the small intestine, with the goal of discovering therapies and related management tools for this widespread but overlooked disease. Ongoing efforts focus on understanding the pivotal role of transglutaminase 2 in triggering the inflammatory response to dietary gluten in the celiac intestine. -
Butrus Khuri-Yakub
Professor (Research) of Electrical Engineering, Emeritus
BioButrus (Pierre) T. Khuri-Yakub is a Professor of Electrical Engineering at Stanford University. He received the BS degree from the American University of Beirut, the MS degree from Dartmouth College, and the Ph.D. degree from Stanford University, all in electrical engineering. His current research interests include medical ultrasound imaging and therapy, ultrasound neuro-stimulation, chemical/biological sensors, gas flow and energy flow sensing, micromachined ultrasonic transducers, and ultrasonic fluid ejectors. He has authored over 600 publications and has been principal inventor or co-inventor of 107 US and international issued patents. He was awarded the Medal of the City of Bordeaux in 1983 for his contributions to Nondestructive Evaluation, the Distinguished Advisor Award of the School of Engineering at Stanford University in 1987, the Distinguished Lecturer Award of the IEEE UFFC society in 1999, a Stanford University Outstanding Inventor Award in 2004, Distinguished Alumnus Award of the School of Engineering of the American University of Beirut in 2005, Stanford Biodesign Certificate of Appreciation for commitment to educate, mentor and inspire Biodesgin Fellows, 2011, and 2011 recipient of IEEE Rayleigh award.
-
Michaela Kiernan
Sr Res Scholar, Medicine - Med/Stanford Prevention Research Center
Current Research and Scholarly InterestsResearch interests include: (1) the design and testing of targeted behavioral interventions that promote long-term lifestyle changes and weight management among subgroups at risk, and (2) the development of methodological and statistical approaches that improve the design, delivery, and analysis of behavioral randomized clinical trials
